![]() Shares of non-voting common stock authorized or outstanding. This determination of affiliate status is not necessarily a conclusive determination for other purposes. ![]() Shares of the registrants common stock held by each officer and director and each beneficial owner of 10% or more of the outstandingĬommon stock of the registrant have been excluded since such persons and beneficial owners may be deemed to be affiliates. The aggregate market value of the voting common equity held by non-affiliates as of June 30, 2010 was $2,251,905,366 based on aĬlosing sale price of $21.82 per share as reported on the NASDAQ Global Select Market on June 30, 2010. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the (Do not check if a smaller reporting company) See the definitions of large accelerated filer, accelerated filer and smaller reportingĬompany in Rule 12b-2 of the Exchange Act. Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to Indicate by check mark if disclosure of delinquent filers pursuant to Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every interactiveĭata file required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months. Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Securities registered pursuant to Section 12(g) of the Act: N/A Name of Each Exchange on Which Registered Securities registered pursuant to Section 12(b) of the Act: (Registrants Telephone Number, Including Area Code): (610) 558-9800 (Exact name of registrant as specified in its charter)ġ00 Endo Boulevard Chadds Ford, Pennsylvania TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Form 10-K Table of ContentsĪNNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.įor the fiscal year ended December 31, 2010 The company was founded in 1997 and is headquartered Dublin, Ireland.Endo Pharmaceuticals Holdings Inc. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Branded Pharmaceuticals segment conducts certain operations in the U.S. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |